Epstein Secrets

e AP (10/22, Marchione) reports that the "antiviral medicine given to hospitalized patients through an IV," being marketed by manufacturer Gilead as Veklury, "cut the time to recovery by five days - from 15 days to 10 on average - in a large study led by the U.S. National Institutes of Health." The drug

es: chief Executive David Solomon, President John Waldron, Chief Financial Officer Stephen Scherr and the head of Goldman's international business, Richard Gnodde will give up $31 million in pay this year. In addition, the bank will take back millions in past pay from Solomon's predecessor, Lloyd Blankfein an

63> (10/22, Marchione) reports that the "antiviral medicine given to hospitalized patients through an IV," being marketed by manufacturer Gilead as Veklury, "cut the time to recovery by five days - from 15 days to 10 on average — in a large study led by the U.S. National Institutes of Health." The drug

es: chief Executive David Solomon, President John Waldron, Chief Financial Officer Stephen Scherr and the head of Goldman's international business, Richard Gnodde will give up $31 million in pay this year. In addition, the bank will take back millions in past pay from Solomon's predecessor, Lloyd Blankfein and

e AP (10/22, Marchione) reports that the "antiviral medicine given to hospitalized patients through an IV," being marketed by manufacturer Gilead as Veklury, "cut the time to recovery by five days - from 15 days to 10 on average - in a large study led by the U.S. National Institutes of Health." The drug

ves: chief Executive David Solomon, President John Waldron, Chief Financial Officer Stephen Scherr and the head of Goldman's international business, Richard Gnodde will give up $31 million in pay this year. In addition, the bank will take back millions in past pay from Solomon's predecessor, Lloyd Blankfein an